stockrow
Friday 6 November 2026
Export AXSM’s income statement to Excel — free account
Axsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
132.13
2.33
+1.80%
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) Revenue
Axsome Therapeutics, Inc.'s revenue for fiscal 2025 was $638.5M, up 65.5% from $385.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $865.3M. Revenue has risen for 3 consecutive fiscal years. Axsome Therapeutics, Inc. ranks 30th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $638.5M | 65.55% |
| FY2024 | $385.7M | 42.53% |
| FY2023 | $270.6M | 440.80% |
| FY2022 | $50.0M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $259.7M | 18.92% |
| Jun 2026 | $218.4M | 14.21% |
| Mar 2026 | $191.2M | (2.45%) |
| Dec 2025 | $196.0M | 14.62% |
| 14 more quarters | Free account |
Revenue against peers
| Company | Revenue |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. compare | $874.1M |
| AXSM Axsome Therapeutics, Inc. | $865.3M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $670.8M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | $280.7M |
| LGND Ligand Pharmaceuticals Incorporated compare | $253.8M |
| PRAX Praxis Precision Medicines, Inc. compare | $8.6M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| ABVX Abivax SA Sponsored ADR compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on AXSM
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement